Replies to post #156535 on Biotech Values

[oc631]

What is your prediction of what will be the first viable oral combo for GT3?

GILD has another NS5A (GS-5816) in Phase 1. Sofosbuvir/GS-5816 could be first to market in GT3 if GILD doesn't license or partner any other compounds.